Tarsier Pharma's planned NYSE American listing, with terms filed in May and updated in July 2026 for roughly 5.6 million shares at $8–10 to raise about $50 million, has not materialized by mid-August amid a subdued environment for small clinical-stage biotechs. Trader consensus at 98.4% against an IPO before September 2026 reflects persistent delays, limited institutional appetite for pre-revenue assets like this Phase 3 ocular therapy developer, and broader equity market caution that has kept comparable offerings sidelined. The implied post-IPO market cap near $294 million at filing now appears aspirational without fresh catalysts. A positive FDA update on its SPA-backed trial, improved biotech IPO volumes, or a strategic partnership could reopen the window, though near-term resolution remains unlikely given the short timeline to September.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयासितंबर 2026 से पहले कोई आईपीओ नहीं 98.4%
$400M-$450M 2.3%
$250M-$300M 2.0%
<$250M 1.3%
$15,112 वॉल्यूम
$15,112 वॉल्यूम
9 जुल, 2026
<$250M
1%
$250M-$300M
2%
$300M-$350M
<1%
$350M-$400M
<1%
$400M-$450M
2%
>$450M
<1%
सितंबर 2026 से पहले कोई आईपीओ नहीं
98%
सितंबर 2026 से पहले कोई आईपीओ नहीं 98.4%
$400M-$450M 2.3%
$250M-$300M 2.0%
<$250M 1.3%
$15,112 वॉल्यूम
$15,112 वॉल्यूम
9 जुल, 2026
<$250M
$907 वॉल्यूम
1%
$250M-$300M
$979 वॉल्यूम
2%
$300M-$350M
$561 वॉल्यूम
<1%
$350M-$400M
$561 वॉल्यूम
<1%
$400M-$450M
$349 वॉल्यूम
2%
>$450M
$680 वॉल्यूम
<1%
सितंबर 2026 से पहले कोई आईपीओ नहीं
$11,075 वॉल्यूम
98%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's planned NYSE American listing, with terms filed in May and updated in July 2026 for roughly 5.6 million shares at $8–10 to raise about $50 million, has not materialized by mid-August amid a subdued environment for small clinical-stage biotechs. Trader consensus at 98.4% against an IPO before September 2026 reflects persistent delays, limited institutional appetite for pre-revenue assets like this Phase 3 ocular therapy developer, and broader equity market caution that has kept comparable offerings sidelined. The implied post-IPO market cap near $294 million at filing now appears aspirational without fresh catalysts. A positive FDA update on its SPA-backed trial, improved biotech IPO volumes, or a strategic partnership could reopen the window, though near-term resolution remains unlikely given the short timeline to September.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
बाज़ार खुला: Jul 7, 2026, 9:12 AM ET
वॉल्यूम
$15,112समाप्ति तिथि
9 जुल, 2026बाज़ार खुला
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's planned NYSE American listing, with terms filed in May and updated in July 2026 for roughly 5.6 million shares at $8–10 to raise about $50 million, has not materialized by mid-August amid a subdued environment for small clinical-stage biotechs. Trader consensus at 98.4% against an IPO before September 2026 reflects persistent delays, limited institutional appetite for pre-revenue assets like this Phase 3 ocular therapy developer, and broader equity market caution that has kept comparable offerings sidelined. The implied post-IPO market cap near $294 million at filing now appears aspirational without fresh catalysts. A positive FDA update on its SPA-backed trial, improved biotech IPO volumes, or a strategic partnership could reopen the window, though near-term resolution remains unlikely given the short timeline to September.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
वॉल्यूम
$15,112समाप्ति तिथि
9 जुल, 2026बाज़ार खुला
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma's planned NYSE American listing, with terms filed in May and updated in July 2026 for roughly 5.6 million shares at $8–10 to raise about $50 million, has not materialized by mid-August amid a subdued environment for small clinical-stage biotechs. Trader consensus at 98.4% against an IPO before September 2026 reflects persistent delays, limited institutional appetite for pre-revenue assets like this Phase 3 ocular therapy developer, and broader equity market caution that has kept comparable offerings sidelined. The implied post-IPO market cap near $294 million at filing now appears aspirational without fresh catalysts. A positive FDA update on its SPA-backed trial, improved biotech IPO volumes, or a strategic partnership could reopen the window, though near-term resolution remains unlikely given the short timeline to September.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न